Pilgrim Global buys Sable Offshore (SOC) shares worth $14.7m
Investing.com - Cantor Fitzgerald maintained its Overweight rating and $100.00 price target on Vera Therapeutics (NASDAQ:VERA) stock ahead of upcoming clinical data presentations. According to InvestingPro data, the stock has shown strong momentum with a 34% gain over the past six months, though technical indicators suggest the stock is currently overbought.
The research firm highlighted atacicept, Vera’s candidate for IgA nephropathy (IgAN) which has received Breakthrough Designation status, as a key reason for its bullish outlook. Vera plans to file a Biologics License Application (BLA) for atacicept this quarter. The company maintains a strong financial position, with a healthy current ratio of 17.03 and more cash than debt on its balance sheet.
Detailed Phase 3 ORIGIN 36-week data supporting the BLA filing is expected to be presented at the American Society of Nephrology conference scheduled for November 6-9.
Cantor Fitzgerald considers VERA shares undervalued at their current $1.9 billion market capitalization, noting the company holds $557 million in cash as of the third quarter of 2025.
The firm anticipates potential approval and launch of atacicept in mid-2026, describing Vera Therapeutics as a "Top Pick" with blockbuster potential in the IgA nephropathy market.
In other recent news, Wolfe Research downgraded Vera Therapeutics from an "Outperform" rating to "Peerperform." This decision was influenced by the company’s lack of significant catalysts that could drive its stock performance. Wolfe Research highlighted that Vera Therapeutics’ shares have fallen by approximately 57% since November. Despite a rally in the broader biotech sector in June, the company’s stock has not shown signs of recovery. This downgrade reflects the research firm’s assessment of the company’s current market challenges. Vera Therapeutics has not provided new developments or earnings reports recently to counteract this analyst sentiment. Investors may want to consider these factors when evaluating the company’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.